Drugs / RGLS8429
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05521191 | Oct 2022 → Jan 2025 | autosomal dominant polycystic kidney disease | Regulus Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05429073 | Jun → Sep 2022 | — | Regulus Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGLS8429 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05429073 ↗ |
| Route | Subcutaneous | “administered via subcutaneous (SC) injection” NCT05429073 ↗ |